Click here to access the analysis showing your margins on both the above product and the alternative funded product.

Bimatoprost-Actavis will be displaying a part charge on your computer system when dispensing this product. However as per previous notification 21 January 2019, ProPharma / PWR have been supplying this product at less than the Pharmaceutical Schedule price and therefore you are able to zero this part charge.

We have limited stock available of Bimatoprost-Actavis which we are selling as shown in the analysis at $1.10 (plus GST) on a first in, first served basis. Once sold, we will automatically replace to Bimatoprost-Multichem.

Note – Bimatoprost-Actavis is funded until 1 May 2019

This is another opportunity to increase your margin on a low value high volume product without risk.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author